We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Barclays PLC: Wrong Business, Wrong Management, Right Price

Barclays PLC (LON:BARC) third-quarter results reveal both past mistakes and future potential

| More on:

You’re reading a free article with opinions that may differ from The Twelfth Magpie’s Premium Investing Services. Become a member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more, and get a free 'Best Buy Now' stock!.

Barclays

Shares in Barclays (LSE: BARC) (NYSE: BCS.US) are up around 1% on news of slightly better than expected third-quarter results, but in reality shareholders have little to cheer.

Should you buy Barclays Plc shares today?

Before you decide, please take a moment to review this report first. Despite ongoing uncertainties from US tariffs to global conflicts, Mark Rogers and his team believe many UK shares still trade at substantial discounts, offering savvy investors plenty of potential opportunities to learn about.

That’s why this could be an ideal time to secure this valuable research – Mark’s analysts have scoured the markets to reveal 5 of his favourite long-term ‘Buys’. Please, don’t make any big decisions before seeing them.

When then-new CEO Antony Jenkins unveiled Project Transform in Feb 2013, prospects for Barclays looked good: apart from its core position in UK retail and commercial banking, it had a world-class investment bank thanks to Bob Diamond’s opportunistic acquisition of Lehman Brothers in the aftermath of the financial crash, together with top-quality franchises in the guise of Barclaycard and Barclays’ African businesses. Project Transform would eliminate the more egregious excesses of the investment bank, restore Barclays’ reputation, slash costs and non-core operations, and push return on equity (RoE) above the cost of capital.

21 months later the shares are down by over 25%, investment banking revenues have fallen off a cliff, the bank is still dogged by litigation for all manner of misbehaviour, and its capital adequacy remains in the balance with tomorrow’s announcement of the results of the Bank of England’s leverage test eagerly anticipated.

What went wrong?

Undoubtedly, the biggest problem has been the investment bank. Resurgent markets should have been good for business, but Barclays’s strengths lay predominantly in so-called FICC; fixed interest, commodities and currency. An unanticipated side-effect of QE has been to reduce the volatility that drives volumes in these markets.

But it also seems that Mr Jenkins — once dubbed Saint Antony — has not proved to be strong enough to manage fat-cat American investment bankers. Nefarious practices continued, such as the unresolved issue of ‘dark’ liquidity pools. Big-hitters called Mr Jenkins’ bluff over pay and bonuses, then promptly left anyway after receiving big payouts. The bank responded by cutting the investment bank further, even as some of it was walking out the door. The equities business, a potential future star performer, shrank by 25% in Q3. That’s value-destructive death-by-a-thousand-cuts: it would have been better to spin off the investment bank in the first place. Wrong business, or wrong management? I think some of both.

The upside

Two things did go right. The surprising boom in the UK economy helped retail and commercial banking: at bottom, banks are a play on the economies they serve. Cost-cutting has been successful with a 7% drop in expenses and a 7,800 headcount reduction — though this may owe more to hard-nut finance director Tushar Morzaria, whose investment banking background might also make him a promising candidate to succeed Mr Jenkins.

Together with good results from Barclaycard, retail and commercial banking contributed 53% of Barclays’ third-quarter core income and 60% of profit. That promises more stable and reliable income in the future, and with RoEs of 12.5% and 18.5% respectively, they should exceed the cost of capital. Barclays’ capital adequacy also looks better, reporting a 3.5% leverage ratio that augurs well for the Bank of England stress-test — but the proof of that pudding will be in the eating…

Cheap

Yet Barclays’ shares are still stuck at 0.8 x tangible net asset value — that’s cheap if RoE remain stable and there aren’t too many unanticipated litigation costs. So I’m holding on to my shares, admittedly with less conviction than before. They’re risky, but the upside is starting to look more plausible than the downside.

Tony Reading owns shares in BArclays. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

This way, That way, The other way - pointing in different directions
Investing Articles

Investec vs Aberdeen: which is the better income stock to buy?

Aiming to boost the average yield of his income portfolio, Mark Hartley's looking for new income stocks to buy on…

Read more »

Asian man looking concerned while studying paperwork at his desk in an office
Investing Articles

Down 41% since January, this quality S&P 500 stock is stinking out my ISA

The tide's turned against this S&P 500 robotics stock. Is it time to dump it? Or is there a no-brainer…

Read more »

GSK scientist holding lab syringe
Investing Articles

By mid-2027, analysts expect £6,000 in GSK shares to be worth…

GSK shares are currently trading almost 20% below their 2026 highs. Is there potential for a rebound over the next…

Read more »

Rolls-Royce's Pearl 10X engine series
Investing Articles

Up nearly 1,400% in 5 years! But are Rolls-Royce shares still secretly undervalued?

After skyrocketing, Rolls-Royce shares are now near an all-time high, but could the engineering giant still have more room to…

Read more »

Happy senior couple hugging and enjoying retirement at home
Investing Articles

By mid-2027, analysts expect £5,000 in Barclays shares to be worth…

Barclays shares have outperformed the FTSE 100 by a wide margin over the last year. And City analysts expect to…

Read more »

Man hanging in the balance over a log at seaside in Scotland
Investing Articles

Near 5-year lows, here’s what the experts say about the Diageo share price

Ben McPoland's questioning his sanity after investing in Diageo. Where do institutional analysts see its share price heading over the…

Read more »

British Airways cabin crew with mobile device
Investing Articles

Up 165% but still with a P/E of 7.9. Is the IAG share price a generational bargain?

The IAG share price has been on fire for the last two years, delivering some of the biggest returns in…

Read more »

Emma Raducanu for Vodafone billboard animation at Piccadilly Circus, London
Investing Articles

Here’s the latest Vodafone share price forecasts for 2027

Up 35% in 12 months, the Vodafone share price is beating the stock market right now, but can this momentum…

Read more »